CALGARY, ALBERTA--(CCNMatthews - April 10, 2007) - Stem Cell Therapeutics Corp. (“SCT”)(TSX VENTURE:SSS) is pleased to announce positive interim results from its currently enrolling Phase IIa- Safety Trial study “Beta-hCG + Erythropoietin in Acute Stroke”. This uncontrolled open label safety trial was designed to determine whether NTxTM-265 could be safely administered to a population of patients with acute stroke. In addition to the trial’s primary safety endpoint, a number of secondary endpoints are being studied to characterize early indicators of efficacy in patients receiving this novel stroke therapy. A review of the design of this clinical trial can be viewed at www.clinicaltrials.gov/ct/show/NCT00362414 and on SCT’s website under Dr. Steven Cramer’s poster presentation from the International Stroke Conference, Feb 2007.
